Disclosure Panels Details Page
Melanoma Panel - Disclosures as of 04/02/2025
|
Panel Member
(Spouse/Domestic Partner/Dependent) |
Clinical Research Support/Data Safety Monitoring Board | Scientific Advisory Boards, Consultant, or Expert Witness | Promotional Advisory Boards, Consultant, or Speakers Bureau | Employment/ Governing Board, Patent, Equity, or Royalty | Date Completed |
|---|---|---|---|---|---|
| Mark Albertini MD | Apeiron Biologics, Vienna, Austria Bristol Myers Squibb Erasca Merck & Co., Inc. |
None | None | None | 02/10/2025 |
| Christopher Barker MD | Amgen Inc. Elekta EMD Serono Merck & Co., Inc. Physical Sciences Incorporated (through subcontracted funds from NIH) Regeneron Pharmactcls |
None | None | None | 02/26/2025 |
| Sarah Bateni MAS,MD | None | None | None | None | 03/27/2025 |
| Joel Baumgartner MD | None | None | None | None | 03/27/2025 |
| Shailender Bhatia MD | EMD Serono Incyte Corporation |
Bristol Myers Squibb Replimune |
None | None | 03/09/2025 |
| Christopher Bichakjian MD | None | None | None | None | 03/27/2025 |
| Marian Birkeland PhD | None | None | None | None | 03/03/2025 |
| Nicole Blankenhorn | None | None | None | None | 02/27/2025 |
| Genevieve Boland PhD,MD | Olink Proteomics Teiko |
Ankyra Therapeutics Iovance pharmaceuticals Merck & Co., Inc. Moderna Novartis Pharmaceuticals Corporation Replimune |
None | Ankyra | 03/08/2025 |
| Sunandana Chandra MD,MS | Alkermes Bristol Myers Squibb Merck & Co., Inc. Novartis Pharmaceuticals Corporation Regeneron Pharmactcls |
Bristol Myers Squibb Novartis Pharmaceuticals Corporation Pfizer Inc. Regeneron Pharmactcls |
None | None | 11/11/2024 |
| David Chen MD,PhD | None | Replimune | None | None | 01/24/2025 |
| Bartosz Chmielowski PhD,MD | Adagene Advenchen Laboratories Ascentage Atreca Bristol Myers Squibb Compugen Georgiamune IDEAYA Biosciences Immunocore Infinity Pharmaceuticals, Inc InstilBio Karyopharm Therapeutics Kezar Life Sciences Kinnate KrystalBio Macrogenics Merck & Co., Inc. Nested Therapeutics Novartis Pharmaceuticals Corporation PACT Pharma Pierre-Fabre Replimune SpringWorks Therapeutics SWOG Trisalus Xencor Xilio |
Pfizer Inc. | None | None | 02/10/2025 |
| Dominick DiMaio MD | None | None | None | None | 03/18/2025 |
| Roxana Dronca MD | Alkermes Bristol Myers Squibb Emerson Collective Phosplatin Therapeutics Regeneron Pharmactcls |
BMS Elsevier, Inc. Replimune |
BMS non accredited BMS internal educational event | None | 11/04/2024 |
| Sara Espinosa PhD | None | None | None | None | 03/07/2025 |
| Martin Fleming MD,FACS | None | None | None | None | 02/13/2025 |
| Anjela Galan MD | None | None | None | None | 03/30/2025 |
| Kristina Gregory MSN,RN | None | None | None | None | 11/12/2024 |
| Samantha Guild JD | None | Melanoma Research Program (CDMRP) State of Texas |
None | None | 02/07/2025 |
| Evelyn Handel BCPS,PharmD,BCOP | None | None | None | None | 03/20/2025 |
| Erin Hesler | None | None | None | None | 03/10/2025 |
| Siwen Hu-Lieskovan PhD,MD | None | Amgen Inc. Endeavor BioMedicines Replimune |
None | None | 11/09/2024 |
| Douglas Johnson MD,MSCI | None | AstraZeneca Pharmaceuticals LP Bristol Myers Squibb Jackson Laboratories Merck & Co., Inc. Novartis Pharmaceuticals Corporation Pfizer Inc. Teiko |
None | Patent for MHC-II as a biomarker for immunotherapy response|Patient for abatacept or belatacept as treatment for refractory irAEs | 03/27/2025 |
| Madeline Joyce OCN,RN,BSN | None | None | None | None | 03/05/2025 |
| Giorgos Karakousis MD | Merck & Co., Inc. | None | None | None | 03/27/2025 |
| Ann Karosas BCOP,RPh | None | None | None | None | 01/13/2025 |
| Kari Kendra PhD,MD | Bristol Myers Squibb GSK Immunocore Melanoma Research Foundation Merck & Co., Inc. National Institute on Aging Varian Medical Systems |
None | None | None | 11/08/2024 |
| Maija Kiuru PhD,MD | NanoString Technologies, Inc. National Institute of Arthritis and Musculoskeletal and Skin Diseases NCI NIH UC Davis |
None | None | None | 03/27/2025 |
| Julie Lange MD,ScM | None | None | None | None | 02/27/2025 |
| Ryan Lanning PhD,MD | None | None | None | None | 03/27/2025 |
| Theodore Logan MD,FACP | Abbott Laboratories Abraxis Bioscience, Inc. Acceleron Pharma, Inc. Amgen Inc. Argos Therapeutics AstraZeneca Pharmaceuticals LP AVEO Pharmaceuticals, Inc. Bristol Myers Squibb Cerulean Pharma Dynavax Technologies Eisai Inc. Eli Lilly and Company EMD Serono GSK Immatics Iovance pharmaceuticals MacroGenics MedImmune Inc. Merck & Co., Inc. Millennium Pharmaceuticals, Inc. NiKang Therapeutics Novartis Pharmaceuticals Corporation Peloton Therapeutics, Inc. Pfizer Inc. Prometheus Roche Laboratories, Inc. sanofi-aventis U.S. Synta Pharmaceuticals Corp. Threshold Pharmaceuticals TRACON Pharmaceuticals, Inc. |
None | None | None | 02/05/2025 |
| Miguel Materin MD | None | AstraZeneca Pharmaceuticals LP Castle Biosciences Ideaya Biosciences |
None | None | 09/07/2024 |
| Christine McLaughlin | None | None | None | None | 02/20/2025 |
| Nicole McMillian MS | None | None | None | None | 01/21/2025 |
| Kelly Nelson MD,FAAD | None | None | None | None | 01/28/2025 |
| Aaron Oliver PharmD | None | None | None | None | 03/18/2025 |
| Daniel Olson MD | AsherBio Astellas Pharma US, Inc. Bayer HealthCare Chimeric Therapeutics CRISPRx Therapeutics Immuneering Immunocore Inhibrix Numab TScan |
Aadi Bristol Myers Squibb Iovance pharmaceuticals Novartis Pharmaceuticals Corporation Replimune |
None | None | 01/30/2025 |
| Anthony Olszanski MD,RPh | Bristol Myers Squibb GSK HiFiBio Immatics Lantern Pfizer Inc. Regeneron Pharmactcls Replimune Shionogi Takeda Pharmaceuticals North America, Inc. Viewpoint |
Anaveon Bristol Myers Squibb IO Biotech Signatera |
None | None | 12/05/2024 |
| Svitlana Ostanina PhD | None | None | None | None | 02/27/2025 |
| Patrick Ott PhD,MD | Agenus Bristol Myers Squibb Genentech, Inc. Merck & Co., Inc. Xencor |
Abalos Genentech, Inc. Immunetune Imunon Merck & Co., Inc. Pharmajet Phio |
None | None | 11/04/2024 |
| Donna Powell CMD,DHSc,RT(T) | None | None | None | None | 11/25/2024 |
| Igor Puzanov MD,FACP,MSCI | NIH NCI P30CA016056 Cancer Center Support Grant - Program Leader 1.2 Calendar Months | Iovance pharmaceuticals | None | Ideaya, Inc. - Stocks | 02/01/2025 |
| Luke Rothermel MD,MPH | M3D inc | M3D inc | None | None | 12/02/2024 |
| April Salama MD | Ascentage Bristol Myers Squibb Ideaya Immunocore Merck & Co., Inc. Olatec Regeneron Pharmactcls Replimune SeaGen |
Bristol Myers Squibb Novartis Pharmaceuticals Corporation |
None | None | 01/24/2025 |
| Rohit Sharma MD | None | None | None | None | 03/31/2025 |
| Arun Singh MD | Castle Bisosciences | AURA ISOAID LLC |
Ideaya Immunocore |
None | 10/21/2024 |
| Andrew Stacey MS,MD | None | None | None | None | 11/12/2024 |
| Susan Swetter MD | None | None | None | None | 03/20/2025 |
| Katy Tsai MD | ABM Therapeutics AstraZeneca Pharmaceuticals LP BioAtla Bristol Myers Squibb Genentech, Inc. Ideaya Merck & Co., Inc. Oncosec OnKure Pfizer Inc. Replimune |
None | None | None | 06/06/2024 |
| Evan Wuthrick MD | None | MyCareGorithm | None | None | 12/02/2024 |
| Yan Xing PhD,MD | None | Bristol Myers Squibb | None | None | 02/28/2025 |